Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study Wang, M., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreylingls, M., Jedrzejczak, W., Johnson, P. W., Spurgeon, S. E., Zhang, L., Baher, L., Cheng, M., Beaupre, D. M., Blum, K. A. AMER SOC HEMATOLOGY. 2014

View details for Web of Science ID 000349242705013